{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001068","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.219625+00:00","generated_at":"2026-06-05T06:30:13.739142+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026","bullets":["Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.","Cash, cash equivalents and investments $132.3M at Dec 31, 2023; 2024 net cash burn guided $63-67M.","Moderna LNP litigation claim construction held Feb 8, 2024; trial set for April 21, 2025.","Phase 2a imdusiran combo data readouts expected H1 2024; third imdusiran Phase 2a trial to start H1 2024.","AB-101 Phase 1a/1b preliminary data (healthy subjects) expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001068","json":"https://secwatch.observer/filing/0001171843-24-001068.json","markdown":"https://secwatch.observer/filing/0001171843-24-001068.md","text":"https://secwatch.observer/filing/0001171843-24-001068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/0001171843-24-001068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/f8k_022924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:30:13.739142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b4f8695a30399a909e66e8b529a487460f25af6","claim":"Arbutus Biopharma Corp reported financial results for Fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023 and certain other information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/0001171843-24-001068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}